{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-005849","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2022-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.434818+00:00","generated_at":"2026-06-27T06:53:52.835091+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Insmed Q4 revenue $56.1M (+36% YoY), net loss $113M; guides 30%+ ARIKAYCE growth in 2022","bullets":["Full-year 2021 revenue $188.5M (vs $164.4M); ARIKAYCE sales $159.5M US, $16.0M Japan, $12.9M Europe/ROW.","Net loss for 2021 $434.7M ($3.88/share) vs $294.1M ($3.01/share); Q4 net loss $113.0M ($0.95/share).","Cash and marketable securities $766.8M; company expects cash runway into 2024.","Brensocatib Phase 3 ASPEN (bronchiectasis) 50% enrolled; topline data expected early 2023.","Director Steinar J. Engelsen not standing for re-election at 2022 Annual Meeting; no disagreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-005849","json":"https://secwatch.observer/filing/0001140361-22-005849.json","markdown":"https://secwatch.observer/filing/0001140361-22-005849.md","text":"https://secwatch.observer/filing/0001140361-22-005849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036122005849/0001140361-22-005849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036122005849/brhc10033810_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T06:53:52.835091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6b437de38","claim":"Steinar J. Engelsen departed as Director at INSMED Inc.","evidence_excerpt":"On February 15, 2022, Steinar J. Engelsen, M.D. notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2022 Annual Meeting of Shareholders (the “Annual Meeting”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1104506/000114036122005849/0001140361-22-005849-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}